Related Experiment Video
Updated: Jul 15, 2026
10:09
Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets
Published on: May 11, 2015
Insulin plus a sulfonylurea agent for treating type 2 diabetes
1Cedars-Sinai Medical Center, Los Angeles, California.
Annals of Internal Medicine
|July 1, 1991
Summary
Combining insulin and sulfonylurea therapy offers only a slight improvement in glycemic control for type 2 diabetes patients. This combination therapy did not achieve normal blood glucose levels and is not recommended for poorly controlled diabetes.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Type 2 diabetes is a chronic metabolic disorder characterized by hyperglycemia.
- Management often involves lifestyle modifications, oral antidiabetic agents, and insulin therapy.
- Combined therapy aims to improve glycemic control when monotherapy is insufficient.
Purpose of the Study:
- To review recent literature on the efficacy of combined insulin and sulfonylurea therapy in type 2 diabetes.
- To evaluate the impact of this combination on glycemic control and insulin requirements.
Main Methods:
- Literature search of MEDLINE (1979-1990) and article references.
- Inclusion of studies comparing insulin alone versus insulin plus sulfonylurea in patients with poorly controlled diabetes.
- Analysis of pre- and post-treatment insulin doses, blood glucose, glycated hemoglobin, C-peptide, and insulin levels.
Main Results:
- Combination therapy showed a modest reduction in glycated hemoglobin levels compared to insulin plus placebo.
- Concurrent trials: 11.1% (placebo) vs. 10.0% (sulfonylurea).
- Cross-over trials: 10.6% (placebo) vs. 9.8% (sulfonylurea).
Conclusions:
- Combined insulin and sulfonylurea therapy provides only slight improvement in glycemic control.
- Reduced exogenous insulin dosage was observed with sulfonylurea use.
- Therapy did not achieve near-normal blood glucose levels; not recommended for poorly controlled type 2 diabetes on insulin.
Related Concept Videos
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...